SCHEMBL4425849

SCHEMBL4425849

CC(CCc1nc2c(ncn2CC(F)F)c(=O)n1-c1ccc(F)cc1)C(F)(F)F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.37
RAB9A P51151 4/20 0.37
ALDH1A1 P00352 4/20 0.37
LMNA P02545 3/20 0.37
HPGD P15428 3/20 0.37
TSHR P16473 3/20 0.37
HKDC1 Q2TB90 2/20 0.37
SMN1; SMN2 Q16637 4/20 0.33
PDE10A Q9Y233 1/20 0.33
ALDH1A3 P47895 1/20 0.32
CTSL P07711 1/20 0.32
ELANE P08246 1/20 0.32
CMA1 P23946 1/20 0.32
CTSS P25774 1/20 0.32
CASP1 P29466 1/20 0.32
CTSC P53634 1/20 0.32
CTSZ Q9UBR2 1/20 0.32
KLK4 Q9Y5K2 1/20 0.32
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4512742 0.92 CNR1 (0.39) NPC1ALDH1A1LMNAHPGDTSHR
SCHEMBL4529223 0.92 HKDC1 (0.40) NPC1RAB9AALDH1A1LMNAHPGD
SCHEMBL4521064 0.87 HKDC1 (0.40) NPC1RAB9AALDH1A1LMNAHPGD
SCHEMBL4510793 0.86 HKDC1 (0.39) NPC1RAB9AALDH1A1LMNAHPGD
SCHEMBL4776876 0.84 NPC1 (0.33) NPC1RAB9AALDH1A1LMNAHPGD
SCHEMBL4521631 0.83 TSHR (0.37) NPC1ALDH1A1LMNATSHRPDE10A
SCHEMBL4510647 0.83 HKDC1 (0.35) NPC1RAB9AALDH1A1LMNAHPGD
SCHEMBL4526037 0.83 NPC1 (0.44) NPC1RAB9AALDH1A1LMNAHPGD
SCHEMBL4531547 0.82 NPC1 (0.35) NPC1RAB9AALDH1A1LMNAHPGD
SCHEMBL4520614 0.82 CNR1 (0.40) NPC1ALDH1A1LMNAHPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2061470-A2 HALOALKYL-SUBSTITUTED PYRIMIDINONE DERIVATIVES Neurogen Corporation (US) 2009-05-27 EP claimed
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US claimed
WO-2008024433-A2 HALOALKYL-SUBSTITUTED PYRIMIDINONE DERIVATIVES NEUROGEN CORPORATION (US) 2008-02-28 WO claimed
US-20090298856-A1 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) BROWN REBECCA ELIZABETH 2009-12-03 US disclosed
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US disclosed
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US disclosed
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives PIGS, GPR174, GPR17 NPC1 1236/4885RAB9A 1308/4885ALDH1A1 461/4885
US-20090298856-A1 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) TRPV1, TRPV2, TRPV4 NPC1 631/4885RAB9A 1675/4885ALDH1A1 897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.